Novartis licenses potential new hepatitis C treatment from Debiopharm
This article was originally published in Scrip
Executive Summary
Novartis has licensed exclusive rights to develop and market Debiopharm's Debio 025 (alisporivir), which is currently in Phase IIb testing for the treatment of hepatitis C.